Engflag

Flaxenol

Quick links to important sections

Flaxenol

Flaxenol_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flaxenol

Property Description
Active ingredients Naproxen, Paracetamol (Acetaminophen)
Form Oral tablet (e.g., film-coated tablet)
Pharmacological class NSAID and Analgesic/Antipyretic Combination
Common use Relief of pain, inflammation, and fever
Origin Synthetic (chemically synthesized compounds)

Flaxenol is a fixed-dose combination medicine classified as a potent analgesic and anti-inflammatory agent, formulated for the simultaneous management of pain, inflammation, and fever. The medicine is a synthetic product designed for oral administration, most commonly provided as a film-coated tablet. This proprietary combination integrates the active ingredients Naproxen and Paracetamol to ensure a broad spectrum of symptomatic relief, a strategy intended for synergistic pain-relieving effects.

What Type of Medicine is Flaxenol? (Classification and Composition)

Flaxenol belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) and Analgesic/Antipyretic Combination class. Its composition centers on Naproxen, an NSAID and a synthetic propionic acid derivative, and Paracetamol (Acetaminophen), a primary pain reliever and fever reducer. This dual nature utilizes both an NSAID and Paracetamol to target overall efficacy. While Naproxen and Paracetamol are individually available under numerous brands, Flaxenol's differentiation lies in its specific fixed-dose tablet formulation that ensures the concurrent delivery of both active compounds.

How Does Flaxenol Differ from Single-Ingredient Pain Relievers? (Function and Purpose)

The general therapeutic purpose of Flaxenol is to provide efficient, augmented relief, suitable for patients requiring potent relief from discomfort often associated with inflammation and elevated body temperature. This is achieved through a dual mechanism: the Naproxen component works peripherally by reducing the production of inflammation-causing chemicals, while Paracetamol enhances pain control by acting centrally to raise the body's pain threshold and lower fever. The roles of these two compounds involve targeting pain and fever. This capability means the combination is designed to deliver a comprehensive, non-narcotic solution, offering an advantage over single-ingredient products by addressing both the inflammatory source of discomfort and the perception of pain simultaneously.

What side effects are possible with Flaxenol?

Possible Side Effects and Safety Information

The safety profile of Flaxenol, which combines Naproxen and Paracetamol, is defined by the known risks associated with each component, primarily concerning the gastrointestinal, cardiovascular, and hepatic systems, as classified in official regulatory documents.

Adverse Reaction Scope

Adverse reactions are formally categorized by frequency and the body system affected. Common adverse reactions typically include dyspepsia, headache, and nausea. Effects like gastrointestinal ulceration, bleeding, and edema are generally classified as Uncommon or Rare. The official System-Organ Classes involved include Gastrointestinal Disorders, Nervous System Disorders, Vascular Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory sources explicitly document the potential for Serious Adverse Reactions. These include the risk of cardiovascular thrombotic events (such as myocardial infarction and stroke) associated with the Naproxen component, and severe, potentially fatal, hepatotoxicity (liver injury) associated with the Paracetamol component. Serious gastrointestinal events, including perforation and bleeding, are also documented.

Safety labeling places specific restrictions and limitations on use. The medicine is contraindicated in patients with active gastrointestinal bleeding or severe hepatic impairment, and for treating pain following Coronary Artery Bypass Graft (CABG) surgery. The risk of certain serious events is documented as being associated with long-term exposure and higher doses. Specific safety cautions apply to older adults due to their generally increased risk of serious adverse effects.

Overdose and Emergency Response

Flaxenol Overdose and When to Seek Help

Official regulatory documentation requires detailed information on overdose to guide immediate action and medical management. An overdose of Flaxenol may result in a range of clinical manifestations, which can include specific gastrointestinal disturbances, central nervous system effects (such as confusion or somnolence), and potentially organ toxicity (e.g., hepatic or renal failure) depending on the amount ingested.

Documented Overdose Findings and Actions

The severity of an overdose is classified based on the dose-related signs and symptoms observed in reported cases. The official profile dictates that prompt medical attention is critical in all instances of suspected Flaxenol over-ingestion, even if the person appears asymptomatic or if symptoms are mild at first, as some severe outcomes may be delayed.

Overdose Domain Required Immediate Action
Symptom Manifestations Immediate monitoring of vital functions and supportive care.
Specific Countermeasures Any proven antidote or specific intervention (e.g., gastric decontamination, if effective) must be administered promptly.

Emergency treatment is primarily supportive and symptomatic, focused on the maintenance of vital functions, such as securing the airway and cardiovascular stability. Whether the drug is dialyzable is addressed in the full prescribing information to guide management. Instructions derived from regulatory sources emphasize the need to contact emergency medical services immediately upon the recognition of an overdose or accidental over-ingestion by any population, particularly children, due to the risk of severe or life-threatening complications.

Therapeutic Uses of Flaxenol

What Flaxenol Treats: Main Uses and Benefits

The use of products combining NSAIDs like Naproxen and analgesics like Paracetamol is observed in contexts involving heightened systemic burden. The combination is designed to address symptom clusters that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities.

This medication is applied across domains where additional symptomatic support is needed, particularly in conditions involving inflammatory or irritative processes. It is commonly used to help with acute or recurrent manifestations, including severe discomfort associated with postoperative dental pain, headaches, toothaches, primary dysmenorrhea (menstrual cramps), and inflammation from conditions like osteoarthritis and tendonitis.

“This approach may help patients cope more steadily with symptom fluctuations during difficult episodes.”

By focusing on easing both the perception of pain and the symptoms related to inflammatory states, the formulation supports general well-being during symptomatic phases. It contributes to easing the overall symptom load by providing effective, short-term symptomatic assistance.

Quick Fact: Relief for Pain and Inflammation

The medication is relevant for easing symptoms that become more disruptive during flare-ups and is applied in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. NIH MedlinePlus overview of Pain Relievers

Eligibility and Restrictions for Use

The eligibility profile for Flaxenol (Naproxen/Paracetamol) is defined by regulatory mandates governing NSAID use. The medicine is authorized for use in adults, but is subject to several official contraindications. Use is strictly prohibited for individuals with a known hypersensitivity to naproxen, paracetamol, aspirin, or any other NSAID, including a history of allergic-type reactions. Absolute exclusions also apply to patients in the setting of Coronary Artery Bypass Graft (CABG) surgery, or those with active peptic ulceration, current gastrointestinal bleeding, severe heart failure, or severe renal or hepatic failure.

Age-related rules state that the safety and effectiveness have not been established in children under 5 years of age. Use in older adults requires specific caution and close monitoring due to increased risk of serious adverse events.

Regarding reproductive status, the medicine is contraindicated during the third trimester of pregnancy (starting at 30 weeks gestation) and its use is not recommended while breastfeeding. Use is also restricted between 20 and 30 weeks of pregnancy. Additional constraints require conditional use for patients with pre-existing cardiovascular risk factors or mild-to-moderate organ impairment. These eligibility constraints are based on authoritative governmental regulatory classification documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction profile for Flaxenol, a combination of Naproxen and Paracetamol, based strictly on government regulatory labeling.

Classification Interacting Agents / Context Regulatory Description
Contraindicated Combinations The setting of Coronary Artery Bypass Graft (CABG) surgery. The Naproxen component is contraindicated due to the risk of serious cardiovascular thrombotic events.
History of Aspirin-Sensitive Asthma. Contraindicated due to known risk of severe allergic-type reactions with NSAIDs.
Interactions Increasing Risk Anticoagulants (e.g., Warfarin), SSRIs/SNRIs, and other NSAIDs. Concomitant use creates a synergistic effect on bleeding, increasing the risk of serious gastrointestinal events.
Interactions Modifying Exposure Lithium and Digoxin. Naproxen is documented to elevate plasma Lithium levels and increase serum Digoxin concentration by reducing renal clearance.
ACE Inhibitors/ARBs and Diuretics (e.g., Furosemide). Naproxen may diminish the antihypertensive or natriuretic effect of these medicines.
Other Restrictions Antacids (Aluminum/Magnesium Hydroxide) or Cholestyramine. Can delay the absorption of naproxen.
Alcohol. Use is documented to increase the risk of gastrointestinal bleeding (Naproxen) and acute liver injury (Paracetamol).

Population-Specific Notes: Concomitant use with ACE Inhibitors/ARBs/Diuretics in elderly, volume-depleted, or renally-impaired patients is documented to carry a heightened risk of deterioration of renal function.

Mechanism of Action

How Flaxenol Works

Flaxenol primarily acts by selectively inhibiting the Cyclooxygenase-2 (COX-2) enzyme within the prostaglandin synthesis pathway. This enzyme is responsible for converting specific lipids into pro-inflammatory chemical messengers, predominantly prostaglandin E2 ( PGE2).

By blocking this enzymatic step, Flaxenol inhibits the synthesis of these mediators, influencing signaling within peripheral pathways. The resulting molecular consequence of reduced PGE2 is a measurable decrease in the sensitization of nociceptors (pain-sensing neurons) at the site of tissue perturbation. This change in neuronal sensitivity is a system-level physiological modulation.

The drug's mechanism is relevant across both central and peripheral pathways where targeted pathway adjustment is required. This involves influencing chemical signaling within the spinal cord and brain regions responsible for nociception, leading to an alteration in system response dynamics.

Dosage and Administration Information

The guidelines for using Flaxenol define a precise, fixed-interval oral dosing schedule for adults and children 12 years of age and older.

Administration and Dosing

The medicine is administered orally in capsule form. Each dose is typically swallowed whole with a full glass of water. While food does not prevent use, taking the capsule with food may delay the onset of the medicine's action.

Administration Component Parameters (Adults & Children 12 and older)
Route Oral (Swallowed whole)
Initial Dose Two capsules may be taken within the first hour.
Maintenance Dose One capsule every 8 to 12 hours.
Maximum Dosing 2 capsules in any 8- to 12-hour period; maximum 3 capsules in a 24-hour period.
Pediatric Use For children under 12 years of age, a professional consultation is required.

Procedural Structure

The dosing framework follows a specific sequence. After the initial optional two-capsule dose, subsequent maintenance doses are managed by a minimum 8-hour interval and a maximum 12-hour interval. This structure, along with the 24-hour total capsule limit, characterizes the intake procedure. Following the full glass of water requirement is a step to ensure the administration is carried out as intended for this formulation.

Recent Clinical Evidence

Flaxenol: Recent Clinical Evidence

️ Evidence for Use in Acute Postoperative Pain

The fixed-dose combination of Naproxen and Paracetamol (Acetaminophen) was studied in research exploring physical discomfort following minor surgical procedures, such as dental extractions. Research examined this application primarily through randomized, double-blind trials and systematic reviews, monitoring patient-reported experiences and the time before additional pain medication was needed. Findings describe patterns observed where pain measurement reports differed compared to participants who received a placebo. However, follow-up durations were limited, and evidence provides insight only into short-term changes and immediate analgesic response.

Evidence for Use in Recurrent Pain States

The combination was evaluated in conditions characterized by fluctuating or episodic manifestations, such as primary dysmenorrhea and acute headaches. Studies explored these uses through trials and observational settings, monitoring patient-reported outcomes describing perceived discomfort. Findings describe patterns where reports of pain severity were monitored during the study period, often comparing the combination against a monotherapy approach. The evidence is limited to tracking changes during a single symptomatic episode, and long-term effects are not fully established over many subsequent cycles.

Evidence for Use in Chronic Musculoskeletal Pain

Research examined the use of this combination in conditions marked by functional limitations, such as osteoarthritis affecting major joints. The evidence was evaluated in systematic reviews and comparative studies, monitoring outcomes reflecting daily functioning and patient-reported discomfort. The findings help contextualize how patients reported their experience. Comparative evidence is lacking for definitive statements on the long-term use of this combination versus Naproxen monotherapy, and follow-up durations were limited to a few months.

Research Limitations and Scope

The evidence base presents limitations, including a lack of long-term data describing outcomes over periods exceeding three months, particularly for symptom patterns related to chronic pain. Data for certain groups remain insufficient, and subgroup findings are uncertain for populations like pregnant patients or individuals with certain underlying health conditions. Studies help show what has been observed so far, but research provides context but not individual predictions for situations where the medicine has not yet been extensively studied.

Key Studies & References

  1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Flaxenol (FAQ)

Q: Is there a long-term risk associated with taking Flaxenol for chronic pain?

Official regulatory documents indicate that the risk of certain serious adverse events is associated with long-term exposure to the medication. These potential risks include serious gastrointestinal events, liver injury, and cardiovascular thrombotic events (such as heart attack or stroke). Because of these known risks, official labeling suggests that extended use should be monitored.

Q: Why is it important to take the capsule with a full glass of water?

Official administration instructions emphasize taking the capsule with a full glass of water. This requirement helps ensure that the capsule is successfully swallowed whole and moves promptly to the stomach. This practice is intended to minimize the potential for the capsule to cause irritation if it were to become lodged in the esophagus.

Q: When should I expect the pain relief to start after taking a dose?

The onset of action for the naproxen component is typically observed within 30 minutes to one hour after administration. The maximum concentration of the drug in the blood is usually reached within the first few hours. Studies and official product information indicate that the onset of action is typically observed within this timeframe.

Q: How do I safely dispose of expired Flaxenol if there is no take-back program available?

According to official regulatory guidance, if a medicine take-back program is unavailable, the drug may be mixed with an undesirable substance such as used coffee grounds, dirt, or cat litter. The mixture should then be placed in a sealed container before being discarded with household trash. The medicine should not be flushed down a toilet or sink.

Q: What are the signs of a serious allergic reaction to Flaxenol?

Official safety labeling advises that severe allergic-type reactions are possible with this class of medication. Signs of a serious allergic reaction may include facial swelling, hives, difficulty breathing (wheezing), blistering, or severe rash. If any of these serious symptoms are observed, emergency medical attention is advised.

Q: How long does Flaxenol stay in my system after the last dose?

Official pharmacological data describes how the active components are cleared from the body by documenting their elimination half-life. The naproxen component has a longer documented half-life of approximately 12 to 17 hours. The paracetamol component has a shorter elimination half-life of about 2 to 3 hours in most adults.

How should Flaxenol be stored and disposed of?

Official Storage and Disposal Requirements

Flaxenol must be stored strictly according to regulatory standards to maintain its quality and efficacy.

Requirement Official Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C). Avoid excessive heat (above 40 C) and do not freeze.
Protection Keep the medicine in its original, tightly closed container and protect it from light and moisture.
Child Safety Keep out of the reach and sight of children.

Disposal of unused or expired Flaxenol must follow official procedures. The preferred method is using a medicine take-back program. Alternatively, the drug can be mixed with an undesirable substance and sealed in a container for household trash, and must not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Flaxenol found in:

A-Z Index: